$PPHM Recent Headlines Peregrine plunges on test data

New Post Public Reply Private Reply Replies (0) Message Board

Jun 30, 2014 at 9:52 AM

$PPHM Recent Headlines

Peregrine plunges on test data 4:17 p.m. June 27, 2013 - Russ Britt
Small-cap makes a splash with FDA nod for cancer drug 3:16 p.m. May 20, 2013 - Russ Britt
Peregrine drug shows promise in pancreatic cancer 1:17 p.m. Feb. 13, 2013 - MarketWatch.com
In focus: Bullish, but overbought 8:06 p.m. Jan. 9, 2013 - Lawrence G. McMillan
Hedge funds are bullish on these stocks 11:57 a.m. Dec. 5, 2012 - Insider Monkey
Peregrine, FDA agree on brain-cancer drug study 11:56 a.m. Dec. 5, 2012 - MarketWatch.com
Drug trial contractors improve efficiency 10:24 a.m. Nov. 16, 2012 - MarketWatch.com
Monday’s biggest gaining and declining stocks 6:42 p.m. Sept. 25, 2012 - Greg Morcroft
Tuesday’s biggest gaining and declining stocks 5:09 p.m. Sept. 25, 2012 - Greg Morcroft
Peregrine Pharma down 86% after test data review 8:27 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine Pharma down 86% in premarket 8:18 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine reviewing Bavituximab results 7:42 a.m. Sept. 24, 2012 - Greg Morcroft
Some previous Bavituximab data not valid

eregrine 7:42 a.m. Sept. 24, 2012 - Greg Morcroft
Monday’s biggest gaining and declining stocks 2:42 p.m. Sept. 10, 2012 - MarketWatch
Regions Financial, Williams-Sonoma hit 52-week highs; Intel, Cisco active 11:11 a.m. Sept. 10, 2012 - blogs.marketwatch.com
Stocks to watch Monday: AIG, Michael Kors, Sears 6:41 a.m. Sept. 10, 2012 - MarketWatch
Peregrine rallies on bavituximab lung-cancer data 1:29 p.m. Sept. 7, 2012 - MarketWatch.com
Monday’s biggest gaining & declining stocks 2:53 p.m. Aug. 27, 2012 - MarketWatch
Peregrine Pharma slides 12% after negative report 2:21 p.m. Aug. 27, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 4:23 p.m. May 21, 2012 - MarketWatch

First Week Of January 2015 Options Trading For Peregrine Pharmaceuticals (PPHM) 11:09 a.m. May 20, 2014 - TheStreet.com
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack 6:00 a.m. May 9, 2014 - TheStreet.com
Peregrine wins law suit 9:24 a.m. May 5, 2014 - Seeking Alpha
Medivation Signs Deal with OncoFusion Therapeutics - Analyst Blog 6:24 p.m. April 24, 2014 - Zacks.com
Interesting PPHM Call Options For June 21st 11:02 a.m. April 23, 2014 - TheStreet.com
Peregrine's Bavituximab has high success rate in animal testing 9:47 a.m. April 7, 2014 - Seeking Alpha
Peregrine Pharmaceuticals (PPHM) Shares March Higher, Can It Continue? - Tale of the Tape 8:39 a.m. March 18, 2014 - Zacks.com
Cel-Sci's Multikine - Potential 21st Century Superdrug 5:41 p.m. March 13, 2014 - Seeking Alpha
Peregrine antibodies boost anti-tumor activity in animal studies 9:47 a.m. March 11, 2014 - Seeking Alpha
Loss Widens at Peregrine, Shares Down - Analyst Blog 9:40 a.m. March 11, 2014 - Zacks.com
Peregrine Pharmaceuticals Management Discusses Q3 2014 Results - Earnings Call Transcript 3:40 p.m. March 7, 2014 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 2:34 p.m. March 7, 2014 - Edgar Online - (EDG = 10Q, 10K)
Peregrine Pharmaceuticals Inc. Discusses Q3 2014 Results (Webcast) 11:55 a.m. March 7, 2014 - Seeking Alpha
Peregrine Move Looks Sustainable, at Least for Now 7:45 a.m. March 6, 2014 - 247WallSt.com
The Race For A Cure For Cancer, The Final Chapter 4:07 p.m. Feb. 19, 2014 - Seeking Alpha
Could Lilly's Ramucirumab kill off Peregrine's Bavituximab? 9:55 a.m. Feb. 19, 2014 - Seeking Alpha
Dear Healthcare Investors: The Correction, It's Here 6:16 a.m. Feb. 4, 2014 - Seeking Alpha
Peregrine Pharmaceuticals (PPHM) Jumps: Stock Up 7.6% - Tale of the Tape 9:51 a.m. Jan. 22, 2014 - Zacks.com
4 Biotechnology Stocks to Sell Now 6:15 a.m. Jan. 15, 2014 - InvestorPlace.com
Fast Track Status for Peregrine Candidate - Analyst Blog 6:20 p.m. Jan. 7, 2014 - Zacks.com

Technical Scrutiny on Biotech Stocks -- Research on Insmed, Peregrine Pharma, CytRx, and Celldex Therapeutics 6:40 a.m. Today - PR Newswire - PRF
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 4:00 p.m. June 10, 2014 - Marketwire
Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma 8:30 a.m. May 30, 2014 - PR Newswire - PRF
Biotech Stocks Scanner -- Research on PDL BioPharma, Cytokinetics, Vical, and Peregrine Pharma 12:41 p.m. May 6, 2014 - PR Newswire - PRF
Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy(R)) in Advanced Melanoma 7:31 a.m. April 23, 2014 - Marketwire
Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS 12:28 p.m. April 10, 2014 - PR Newswire - PRF
Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer 11:01 a.m. April 9, 2014 - Marketwire
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma 1:15 p.m. April 8, 2014 - PR Newswire - PRF
Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung Cancer 8:04 a.m. April 7, 2014 - Marketwire
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting 4:01 p.m. April 1, 2014 - Marketwire
Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer 8:02 a.m. March 14, 2014 - Marketwire
Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies 8:02 a.m. March 13, 2014 - Marketwire
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 4:11 p.m. March 11, 2014 - Marketwire
Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies 8:04 a.m. March 11, 2014 - Marketwire
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2014 Financial Results and Recent Developments 9:01 a.m. March 7, 2014 - Marketwire
Pre-Market Review of Top Gainers: Canadian Solar, Qihoo 360 Technology, Peregrine Pharma, Renren, and UTi Worldwide 11:40 a.m. March 5, 2014 - PR Newswire - PRF
Peregrine Pharmaceuticals PS-Targeting Immunotherapy Platform to Be Highlighted in Three Data Presentations at Keystone Symposia Conferences 5:01 p.m. March 4, 2014 - Marketwire
Peregrine Pharmaceuticals to Report Third Quarter Fiscal Year 2014 Financial Results Before Market Open on March 7, 2014 5:01 p.m. Feb. 27, 2014 - Marketwire
Peregrine Pharmaceuticals Announces Partial Exercise of Overallotment Option in Connection With Preferred Stock Offering 1:20 p.m. Feb. 27, 2014 - Marketwire
Hercules Offshore Losses Decrease from $121 million to $27 million 10:17 a.m. Feb. 24, 2014 - ACCESSWIRE

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Booming Door Market: $105.93B by 2031, Key Insights

Introduction to the Future of the Door Industry Here's what gets me grinning—despite the market doomsayers, there's one industry that's swinging open new opportunities every year: doors. Projected to hit a whopping $105.93 billion by 2031, this market isn't just about hinges and handles. It's a sign of booming construction, urban development, and rising consumer...

BioMarin Strikes Deal for New Fabry Disease Therapy

BioMarin's Latest Moves in Rare Disease Therapies Now here's a plot twist in the biotechnology landscape. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) just did what they do best—snagging rights to a promising enzyme therapy aimed at turning the tide for Fabry disease. In a deal that spoke volumes about their intentions, BioMarin is forking over a cool $70 million upfront...

Grupo Simec 2026 Nine-Month Financial Surge Spells Change

Sharp Climb in Net Income Sparks Interest Buckle up, folks. Grupo Simec's nine-month results for 2026 are a mixed bag of surprises and steady flows. Let’s break it down: the net income skyrocketed by a whopping 428% compared to the same period last year—jumping from Ps. 763 million to Ps. 4,028 million. That's a solid leap, and it’s largely due to turning a hefty...

Fan Creations Shine: McLaren's Unique Livery Unveiled

From Sticker Dreams to Racing Reality Some days bring surprises outside the typical ticker watch as those market charts get shoved aside, right when fans' stories race onto the scene. What McLaren and Velo cooked up for the Mexico City Grand Prix has got me pausing—a blend of motorsport passion and grassroots creativity. By unveiling the 'Livery of Dreams,' McLaren puts...

Bluevua Partners with Orlando Solar Bears

Bluevua Takes Aim at Bigger Waters Bluevua's move to partner with the Orlando Solar Bears ain't just some casual sponsorship. It’s a statement, loud and clear, that they're ready to play in the big leagues. By sliding into this relationship, they’re not only flexing their branding muscles but also tapping into a vibrant sports market. It’s a clever game plan to...

West Fraser Tackles Grim Quarter: Indefinite Mill Closures

Bracing For Impact: The Tough Truth About West Fraser's Recent Moves Things are looking a bit bleak over at West Fraser Timber Co. They've just dropped their Q3 2026 results, ringing the bell with a hefty $80 million loss. As if that wasn't enough, the company's decided to indefinitely curtail a couple of mills—one in Lanett, Alabama and the other in Leola, Arkansas....

DAR Logs Massive 587,000 Service Hours Nationwide

A Month of Patriotism and Service You've got to hand it to the Daughters of the American Revolution (DAR)—when they commit, they go all in. This year, they turned their usual Day of Service into a full-blown Month of Service, packing in over 587,000 hours of volunteering nationwide. From historic spots to food pantries, DAR members showed up, and honestly, it's the kind...

Hehe Forum Stirs Global Harmony in Taizhou, China

Reflecting on Hehe Culture's Impact Seems like everyone and their neighbor are flocking to Taizhou for the annual Hehe Culture Forum. It's not your run-of-the-mill gathering; more than 220 folks from 23 different countries showed up, diving deep into the murky waters of cultural exchange, global governance, and international cooperation. Now, if you think it's just...

Hyundai and Texas Children's Boost Child Safety in Houston

A Meaningful Partnership for Safer Houston Roads There's a good feeling about corporations genuinely pitching in for community welfare, and Hyundai teaming up with Texas Children's Hospital to boost child passenger safety around Houston is exactly that. Pairing philanthropy with safety is more than just a business move—it's a testament to human decency. With a $25,000...

Ex-Guard Pushes Cost-Saving Grille Guards as Deer Season Hits

Deer Season's Bumper Problem If you're driving a hefty pickup or van in the thick of deer season, forget looking at pretty autumn leaves. Instead, brace for the telltale thud—and the ensuing financial headache—that comes with a deer collision. Anyone who's tangled with such a mishap knows it's not just about the dent in your fender; it's about your wallet getting...